Feb 25 (Reuters) - Alcon on Tuesday forecast 2026 sales growth largely in line with market estimates and guided for a ...

Sustainable Growth Advisers (SGA), an investment management company, released its fourth-quarter investor letter for its ...

Implantables net sales were $474 million, an increase of 4%. Excluding favorable currency impacts of 2%, Implantables net sales increased 2% constant currency. This growth reflects strong performance ...

ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the ...

Q4 2025 Management View CEO David Endicott emphasized that "the second half of 2025 and especially the fourth quarter demonstrated the strength and momentum of our business." He highlighted recent ...

Total30 multifocal for astigmatism, a monthly toric lens for patients with presbyopia, is now available in the U.S., ...

It was business as usual for Alcon, the global eyecare company with manufacturing and research facilities in Berks County.

Please provide your email address to receive an email when new articles are posted on . Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half ...

On Friday, KeyBanc analyst Brett Fishbin revised the price target for Alcon Inc. (NYSE: NYSE:ALC) to $105.00, down from the previous target of $107.00, while continuing to endorse the stock with an ...

Alcon, Inc. ALC delivered fourth-quarter 2025 core earnings per share (EPS) of 78 cents, up 8.3% from the year-ago quarter’s ...

Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product ...